Melvin M. Evers

2.1k citations

39 papers · 1.6k indexed · h-index 22

Impact in

Cellular and Molecular Neuroscience top 2%
- Genetic Neurodegenerative Diseases
Genetics top 5%
- Neurogenetic and Muscular Disorders Research
- Virus-based gene therapy research

Papers in

Cellular and Molecular Neuroscience 23
- Genetic Neurodegenerative Diseases 23
Molecular Biology 34
- Mitochondrial Function and Pathology 12
- Muscle Physiology and Disorders 10
- RNA Research and Splicing 9
- CRISPR and Genetic Engineering 5
- Ubiquitin and proteasome pathways 5

Co-authors: Willeke van Roon‐Mom Lodewijk J.A. Toonen Pavlina Konstantinova S J van Deventer Jana Miniarikova Martin B. Rook Marti F.A. Bierhuizen Marc A. Vos
Journals: Molecular Therapy — Methods & Clinical Development (5 papers)Neurology (3 papers)Molecular Therapy (2 papers)Brain (2 papers)Nucleic Acid Therapeutics (2 papers)
Partner nations: Netherlands Italy Canada

In The Last Decade

Melvin M. Evers

39 papers receiving 1.5k citations

Peers

Countries citing papers authored by Melvin M. Evers

Since Specialization

Citations

This map shows the geographic impact of Melvin M. Evers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin M. Evers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin M. Evers more than expected).

Fields of papers citing papers by Melvin M. Evers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin M. Evers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin M. Evers. The network helps show where Melvin M. Evers may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Melvin M. Evers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Melvin M. Evers Line = papers co-authored together Melvin M. Evers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models Brain ·M.J. Przegalinska, Christian Landles, Nicholas S. Caron, Erich Dethleffsen, Georgina F Osborne, Michael R. Hayden, David Howland, Sander van Deventer, Gillian P. Bates, Astrid Vallès, Melvin M. Evers	2024	9
2	miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3 Nucleic Acid Therapeutics ·Rui Jorge Nobre, J. K. Chakravarrty, Rikesih M Muralitharan, Sónia Duarte, Sara Lopes, Amal El-Zoghby, Ülkü Arslan, I. Ya. Dyad'kino, Lukas Schwarz, Abdehamid El Mousadik, Valérie Ferreira, Astrid Vallès, Luís Pereira de Almeida, Melvin M. Evers, Lodewijk J.A. Toonen	2021	13
3	Transduction profiles in minipig following MRI guided delivery of AAV-5 into thalamic and corona radiata areas Journal of Neuroscience Methods ·Aisha Kamalodeen, Stephan M. Pouw, Jiřı́ Klı́ma, Zdeňka Ellederová, C. M. Smith., Jan Chrastina, (unknown), Dušan Urgošík, Zdeněk Stárek, Michal Crha, Owen Lewis, Y. Rouillard, Dave Johnson, Cynthia Brouwers, Melvin M. Evers, Jan Motlík, Gerard J.M. Martens, Pavlina Konstantinova, Bas Blits	2021	1
4	Transfer of Therapeutic miRNAs Within Extracellular Vesicles Secreted from Huntington’s Disease iPSC-derived Neurons (4548) Neurology ·M.J. Przegalinska, Jana Miniarikova, Erika Nieves Melendez Hualinga, Sander van Deventer, Pavlina Konstantinova, Melvin M. Evers	2020	4
5	Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain Molecular Therapy — Methods & Clinical Development ·Yang Lan, M.J. Przegalinska, 鶴義仙石, Vivi M. Heine, Pavlina Konstantinova, S J van Deventer, Katja C. Wolthers, Dasja Pajkrt, Adithya Sridhar, Melvin M. Evers	2020	26
6	Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy Molecular Therapy — Nucleic Acids ·Raygene Martier, Jolanda M.P. Liefhebber, Ana Garcı́a-Osta, Jana Miniarikova, Mar Cuadrado‐Tejedor, María Espelosin, Susana Ursúa, Harald Petry, S J van Deventer, Melvin M. Evers, Pavlina Konstantinova	2019	76
7	Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease Molecular Therapy — Methods & Clinical Development ·Raygene Martier, M.J. Przegalinska, 詹淳惠, Jeannette Hübener‐Schmid, V KNUDSEN, Jiřı́ Klı́ma, Lodewijk J.A. Toonen, Štefan Juhás, Jana Juhásová, Zdeňka Ellederová, Jan Motlík, Abhilasha Bansal, Sander van Deventer, Pavlina Konstantinova, Huu Phuc Nguyen, Melvin M. Evers	2019	35
8	Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients Molecular Therapy — Nucleic Acids ·Raygene Martier, Jolanda M.P. Liefhebber, Jana Miniarikova, Elham Rahmanianfar, Jolanda Snapper, I. Kolder, Harald Petry, S J van Deventer, Melvin M. Evers, Pavlina Konstantinova	2019	47
9	AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models Molecular Therapy — Methods & Clinical Development ·О.А Дворянкин, Cynthia Brouwers, Astrid Vallès, Martin de Haan, Harald Petry, S J van Deventer, Pavlina Konstantinova, Melvin M. Evers	2019	54
10	AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model Molecular Therapy ·Melvin M. Evers, Jana Miniarikova, Štefan Juhás, Astrid Vallès, C. M. Smith., Jana Juhásová, Helena Kupcová Skalníková, Petr Vodička, P. Jannasch, Cynthia Brouwers, Bas Blits, Jacek Lubelski, Hana Kovářová, Zdeňka Ellederová, S J van Deventer, Harald Petry, Jan Motlík, Pavlina Konstantinova	2018	122
11	Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model Molecular Neurodegeneration ·Lodewijk J.A. Toonen, Maurice Overzier, Melvin M. Evers, Leticia G. León, А.С. Шабека, Hailiang Mei, Szymon M. Kiełbasa, Jelle J. Goeman, Kristina Hettne, Ólafur Þ. Magnússon, Boudine Lohlun, Alexandre Seyer, Peter A.C. ’t Hoen, Willeke van Roon‐Mom	2018	60
12	Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic Molecular Therapy ·Jana Miniarikova, Melvin M. Evers, Pavlina Konstantinova	2018	36
13	AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease Gene Therapy ·Jana Miniarikova, Kira Schröder, Raygene Martier, Cynthia Brouwers, Catherine Pythoud, Kevin Richetin, M. Rey, Jacek Lubelski, Melvin M. Evers, S J van Deventer, Harald Petry, Nicole Déglon, Pavlina Konstantinova	2017	80
14	In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington’s disease Biomedicine & Pharmacotherapy ·Rok Fajt, Lodewijk J.A. Toonen, Melvin M. Evers, Ali Jahanshahi, Willeke van Roon‐Mom, Yasin Temel	2016	8
15	Antisense oligonucleotides in therapy for neurodegenerative disorders Advanced Drug Delivery Reviews ·Melvin M. Evers, Lodewijk J.A. Toonen, Willeke van Roon‐Mom	2015	230
16	Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies Molecular Neurobiology ·Melvin M. Evers, Lodewijk J.A. Toonen, Willeke van Roon‐Mom	2013	69
17	Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon Neurobiology of Disease ·Melvin M. Evers, 河本陽子, Ioannis Zalachoras, Barry A. Pepers, Onno C. Meijer, Johan T. den Dunnen, Gert‐Jan B. van Ommen, Annemieke Aartsma‐Rus, Willeke van Roon‐Mom	2013	60
18	Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain Frontiers in Molecular Neuroscience ·Ioannis Zalachoras, Melvin M. Evers, Willeke van Roon‐Mom, Annemieke Aartsma‐Rus, Onno C. Meijer	2011	17
19	Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide PLoS ONE ·Melvin M. Evers, Barry A. Pepers, J.C.T. van Deutekom, Susan Mulders, Johan T. den Dunnen, Annemieke Aartsma‐Rus, Gert‐Jan B. van Ommen, Willeke van Roon‐Mom	2011	78
20	A unique residue in rab3c determines the interaction with novel binding protein Zwint‐1 FEBS Letters ·Thijs van Vlijmen, Mathijs Vleugel, Melvin M. Evers, Shabaz Mohammed, Phebe S. Wulf, Albert J. R. Heck, Casper C. Hoogenraad, Peter van der Sluijs	2008	27

About Melvin M. Evers

Melvin M. Evers is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology, Genetics, Neurology and Developmental Neuroscience, having authored 39 papers that have together received 1.6k indexed citations. Recurring topics across this work include Genetic Neurodegenerative Diseases (23 papers), Mitochondrial Function and Pathology (12 papers), Muscle Physiology and Disorders (10 papers), RNA Research and Splicing (9 papers), Virus-based gene therapy research (5 papers), Neurogenetic and Muscular Disorders Research (5 papers), CRISPR and Genetic Engineering (5 papers) and Ubiquitin and proteasome pathways (5 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (671 citations), Genetics (207 citations), Molecular Biology (1.3k citations), Neurology (264 citations) and Cardiology and Cardiovascular Medicine (186 citations). Melvin M. Evers has collaborated with scholars based in Netherlands, Italy and Canada. Frequent co-authors include Willeke van Roon‐Mom, Lodewijk J.A. Toonen, Pavlina Konstantinova, S J van Deventer, Jana Miniarikova, Martin B. Rook, Marti F.A. Bierhuizen, Marc A. Vos, Harald Petry and Cynthia Brouwers. Their work appears in journals such as Molecular Therapy — Methods & Clinical Development, Neurology, Molecular Therapy, Brain and Nucleic Acid Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact